ACID ADDITION SALTS OF N-ETHYI-N'-[2-METHOXY-4-(5-METHYI-4-PRYIMIDIN-2-YL)PHENYL]UREA AND USES THEREOF
The present invention provides an acid addition salt of N-ethyl-N′-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2-yl)phenyl]urea and uses thereof including a method for the treatment of a hyperproliferation-related disorder. The present invention also provides a pharmaceutical composition comprising an acid addition salt of N-ethyl-N′-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2-yl)phenyl]urea.
1 . An acid addition salt of a compound of Formula I:
2 . An acid addition salt according claim 1 , wherein the acid is selected from the group consisting of citric acid, hydrochloric acid, methanesulfonic acid, oxalic acid and tartaric acid.
3 . An acid addition salt according to claim 1 , wherein the salt is a citric acid addition salt.
4 . An acid addition salt according to claim 1 , wherein the salt is a hydrochloric acid addition salt.
5 . An acid addition salt according to claim 1 , wherein the salt is a methanesulfonic acid addition salt.
6 . An acid addition salt according to claim 1 , wherein the salt is an oxalic acid addition salt.
7 . An acid addition salt according to claim 1 , wherein the salt is a tartaric acid addition salt.
8 . An acid addition salt according to claim 1 , wherein the salt is in a crystalline form.
9 . A method of treating a hyperproliferation-related disorder, wherein the method comprises the administration of an acid addition salt according to claim 1 .
10 . A method according to claim 9 , wherein the hyperproliferation-related disorder is treatable by the modulation of microtubule polymerisation.
11 . A method according to claim 9 , wherein the hyperproliferation-related disorder is selected from the group including cancer, viral and bacterial infections, vascular restenosis, inflammatory diseases, autoimmune diseases and psoriasis.
12 - 14 . (canceled)
15 . A pharmaceutical composition comprising:
an acid addition salt according to claim 1 and a pharmaceutically acceptable carrier.